RHPN2
RHPN2 (Rhophilin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Non-small-cell lung cancer.
Overview
Binds specifically to GTP-Rho. May function in a Rho pathway to limit stress fibre formation and/or increase the turnover of F-actin structures in the absence of high levels of RhoA activity.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.64, somatic mutation 0.78). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RHPN2 (Rhophilin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Non-small-cell lung cancer.
- 1 · What it is
RHPN2 (Rhophilin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Binds specifically to GTP-Rho. May function in a Rho pathway to limit stress fibre formation and/or increase the turnover of F-actin structures in the absence of high levels of RhoA activity.
- 3 · How drugs use it
No product in this corpus aims at RHPN2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:19974 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8IUC4 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000131941 (association with cancer (MONDO_0004992) 0.62; (GraphQL API, CC0)); IntOGen RHPN2 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Binds specifically to GTP-Rho. May function in a Rho pathway to limit stress fibre formation and/or increase the turnover of F-actin structures in the absence of high levels of RhoA activity. Location: Cytoplasm, perinuclear region (UniProt). Locus 19q13.11 (HGNC).
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
- Non-small-cell lung cancer: IntOGen driver in 2 cohorts (LUAD, LUSC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RHPN2" OR ABSTRACT:"RHPN2" OR TITLE:"rhophilin Rho GTPase binding protein 2" OR ABSTRACT:"rhophilin Rho GTPase binding protein 2" OR TITLE:"Rhophilin-2" OR ABSTRACT:"Rhophilin-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RHPN2, not a curated reading list.